Oct 18 (Reuters) - Halozyme Therapeutics , which specializes in reformulating drug products available only as infusions, said a pivotal trial of subcutaneous Herceptin, the cancer drug sold by Roche , ...
Sept. 1, 2005 — The U.S. Food and Drug Administration (FDA) and Genentech, Inc., have warned healthcare professionals via letter of study data linking trastuzumab (Herceptin) therapy to a ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved trastuzumab-strf as a biosimilar to trastuzumab for the treatment of certain patients with ...
Among patients with HR+/HER2+ breast cancer, Herceptin and Perjeta plus endocrine therapy proved to be beneficial without chemotherapy. Treatment with Herceptin (trastuzumab) and Perjeta (pertuzumab) ...
LOS ANGELES, May 15 (Reuters) - A combination of targeted cancer drugs -- GlaxoSmithKline Plc's Tykerb and Genentech Inc's Herceptin -- works better than Tykerb alone in women with advanced breast ...
TX05-03e: Adjuvant treatment following neoadjuvant treatment and surgical resection in TX05-03, a trial comparing the safety, efficacy, and immunogenicity of trastuzumab biosimilar candidate (TX05) ...
Roche’s blockbuster breast cancer treatment Herceptin will face more competition after Pfizer’s biosimilar won FDA approval March 11, according to Reuters. The FDA has already approved biosimilar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback